Truth in science.
Transformation in medicine.
At Vera Therapeutics, we pursue truth in science to transform medicine in autoimmune diseases, starting with the kidney.
Rigorous science
We focus on upstream immune pathways that drive disease, asking hard questions and following the evidence.
Patient-centered
We listen closely to patients and caregivers, so their experiences help shape how we approach disease, not just how we measure it.
Designed with intention
Vera Therapeutics was designed to think long term, with independent and disciplined focus on the work that meaningful progress requires.
OUR FOCUS
Committed to IgA nephropathy
We are deeply focused on IgA nephropathy, where the immune drivers of disease remain largely unaddressed and patient need is high.
FEATURED news
September 15, 2026
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
- TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.
- Favorable safety profile, and generally comparable to placebo.
- Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks.
- Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026.
Built on truth, driven by science
We challenge long-standing assumptions in nephrology by combining rigorous science with a deep respect for the lived experience to turn discovery into meaningful progress.
Patient stories
We listen to the lived experiences of people affected by disease. Their perspectives help shape how we pursue new approaches and measure progress.
Working at Vera Therapeutics
We move with purpose, uphold scientific rigor, and value the perspectives that help us see the whole human experience behind complex disease.
Investor & Media Relations
Access our investor and media relations center for company news, financial information, and resources for analysts and journalists.